Are you one of the millions of people that suffer from psoriasis or psoriatic arthritis? If so, you’ve likely heard of the drugs Taltz and Cosentyx. Both medications have been proven to be effective in reducing the symptoms associated with these conditions, but what is the difference between the two? Many patients and healthcare professionals have been asking this question, and for good reason.
To start, Taltz and Cosentyx are both classified as biologic medications, meaning they are derived from living cells and target specific parts of the immune system. They are designed to treat the underlying causes of psoriasis and psoriatic arthritis, by blocking certain proteins that contribute to inflammation. While both drugs work in similar ways, there are some key differences to take note of.
One of the main differences between Taltz and Cosentyx is their active ingredients. Taltz contains ixekizumab, which is a monoclonal antibody that selectively targets a protein called interleukin-17A. Cosentyx, on the other hand, contains secukinumab, which targets a different protein called interleukin-17A. Another difference is the way the drugs are administered. Taltz is given as an injection under the skin every four weeks, while Cosentyx can be given as an injection or as a self-administered prefilled syringe, either every four weeks or every two weeks, depending on the dosage.
Overview of Taltz and Cosentyx
Taltz and Cosentyx are two different drugs used in the treatment of moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Both drugs are classified as biologics, which are made from living cells and work by targeting specific parts of the immune system.
Taltz, also known as ixekizumab, is manufactured by Eli Lilly and Company and was approved by the FDA in 2016. It is administered via self-injection and works by blocking the activity of a protein called interleukin-17A, which contributes to inflammation in the body. The drug is typically prescribed for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, and has been shown to be effective in clinical trials.
Cosentyx, also known as secukinumab, is manufactured by Novartis and was approved by the FDA in 2015. It is administered via self-injection or infusion and works by blocking the activity of a protein called interleukin-17A, which is involved in inflammation. The drug is used to treat a variety of conditions, including moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It has been shown to be effective in clinical trials, and is considered a first-line treatment for psoriasis.
Mechanisms of Action
Taltz and Cosentyx are two biologic drugs used to treat psoriasis and other autoimmune disorders. They belong to a class of drugs called advanced interleukin (IL)-17 inhibitors, also known as IL-17 blockers, which target a specific chemical messenger in the body’s immune system called interleukin-17.
- IL-17 is a cytokine, a protein involved in the inflammatory response.
- IL-17 is produced by T-cells.
- IL-17 is involved in the development and maintenance of chronic inflammation associated with autoimmune diseases, such as psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Taltz and Cosentyx work by neutralizing IL-17 and preventing it from binding to its receptors on the surface of certain cells, thereby reducing inflammation and other symptoms of autoimmune diseases.
The major difference between Taltz and Cosentyx lies in the specific subtypes of IL-17 that they block and the way they bind to the IL-17 receptor. Taltz selectively blocks IL-17A, while Cosentyx selectively blocks IL-17A and IL-17F. Additionally, Taltz binds to the IL-17A homodimer, while Cosentyx binds to the IL-17A/F heterodimer.
| Drug Name | Target IL-17 Subtypes | Receptor Binding Mechanism |
|---|---|---|
| Taltz | IL-17A | IL-17A homodimer |
| Cosentyx | IL-17A and IL-17F | IL-17A/F heterodimer |
Despite these differences, both Taltz and Cosentyx have been shown to be effective in reducing the severity of psoriasis and other autoimmune disorders. Which drug is best for an individual patient depends on various factors, such as the type and severity of the disease, the patient’s medical history and current medications, and their individual response to the drug.
Clinical Applications
Both Taltz and Cosentyx are used to treat psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). They are both classified as biologic drugs, meaning they are created by living organisms and designed to target specific parts of the immune system.
Differences in Clinical Applications
- Taltz is approved for the treatment of moderate to severe plaque psoriasis, active PsA, and active AS. It targets interleukin-17A (IL-17A), a protein that is involved in the development of inflammatory diseases. By blocking IL-17A, Taltz reduces inflammation and improves symptoms of psoriasis and PsA.
- Cosentyx is approved for the treatment of moderate to severe plaque psoriasis, active PsA, active AS, and non-radiographic axial spondyloarthritis (nr-axSpA). It targets interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two proteins that contribute to inflammation in psoriasis and PsA. Cosentyx also targets interleukin-17A in AS and nr-axSpA.
- Cosentyx has an additional indication for the treatment of active psoriatic arthritis in pediatric patients ages 6 and older.
Commonalities in Clinical Applications
Both Taltz and Cosentyx are effective in reducing symptoms of psoriasis, psoriatic arthritis, and ankylosing spondylitis. They are administered by injection and require ongoing treatment to maintain efficacy. Treatment plans should be individualized to each patient’s specific needs and medical history. It is important to consult with a healthcare provider to determine the most appropriate treatment plan.
Comparing Clinical Applications with a Table
| Indication | Taltz | Cosentyx |
|---|---|---|
| Plaque psoriasis | Approved | Approved |
| Psoriatic arthritis (PsA) | Approved (active PsA) | Approved (active PsA and pediatric patients ages 6 and older) |
| Ankylosing spondylitis (AS) | Approved (active AS) | Approved (active AS and non-radiographic axial spondyloarthritis) |
| Targeted proteins | Interleukin-17A | Interleukin-17A and interleukin-17F |
This table summarizes the differences between Taltz and Cosentyx in their approved clinical applications and targeted proteins.
Safety and Side Effects
Both Taltz and Cosentyx are effective medications for treating psoriasis and psoriatic arthritis. However, when it comes to safety and side effects, there are some notable differences between the two drugs.
- Taltz: Studies have shown that Taltz is generally safe and well-tolerated by most patients. However, like any medication, it does come with the risk of side effects. Some of the most common side effects include injection site reactions, upper respiratory tract infections, and nausea. There have also been reports of more serious side effects such as infections, allergic reactions, and inflammatory bowel disease.
- Cosentyx: Cosentyx is generally considered to be a safe medication as well. The most common side effects seen with Cosentyx are injection site reactions, upper respiratory infections, and diarrhea. Like Taltz, there have been reports of more serious side effects such as infections and allergic reactions, as well as rare cases of liver injury and increased risk of tuberculosis.
It’s important to note that both medications come with risks and potential side effects, and patients should always speak with their healthcare provider about any concerns they may have. It’s also important to carefully follow the instructions for use and to report any side effects or adverse reactions to your healthcare provider.
Here is a comparison table of the most common side effects associated with Taltz and Cosentyx:
| Side Effect | Taltz | Cosentyx |
|---|---|---|
| Injection site reactions | Common | Common |
| Upper respiratory tract infections | Common | Common |
| Nausea | Common | Rare |
| Diarrhea | Rare | Common |
| Infections | Rare but serious | Rare but serious |
In summary, both Taltz and Cosentyx are effective medications for treating psoriasis and psoriatic arthritis. When it comes to safety and side effects, Taltz and Cosentyx share many of the same potential risks and side effects, but there are some notable differences between the two drugs. Patients should always consult with their healthcare provider to determine which medication is the best option for their specific needs and medical history.
Dosage and Administration
Taltz and Cosentyx are both prescription medications that require careful dosage and administration. Patients should follow their doctor’s instructions carefully to ensure the medication is used safely and effectively.
- Taltz is available as a subcutaneous injection (a type of injection that is administered under the skin) that is taken once a week for the first three doses, then every four weeks thereafter. The medication is available in single-dose prefilled syringes or single-dose prefilled pens. After proper training, patients can self-inject at home or have a caregiver assist them.
- Cosentyx is also administered as a subcutaneous injection and is available in prefilled syringes or autoinjectors. The recommended dosage depends on the patient’s health condition. For moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, the recommended starting dose is 150 mg. For moderate to severe plaque psoriasis, the recommended starting dose is 300 mg. After the initial dosage, the medication is taken every four weeks.
- Both Taltz and Cosentyx should be stored in the refrigerator until they are ready to be used. Prior to injecting the medication, it should be allowed to sit at room temperature for around 30 minutes to warm up to room temperature. The injection site should be clean and sterile. The medication should also be inspected visually prior to use to ensure there are no particulates or discoloration.
If patients have any questions or concerns regarding the dosage or administration of either medication, they should consult with their healthcare provider. It is important to take Taltz or Cosentyx as directed and not to alter the dosage or schedule without first consulting with a healthcare professional.
| Medication | Dosage | Administration |
|---|---|---|
| Taltz | Varies by condition | Subcutaneous injection |
| Cosentyx | Varies by condition | Subcutaneous injection |
Overall, both Taltz and Cosentyx are effective medications for treating a variety of autoimmune conditions. Patients should work closely with their healthcare provider to determine the best medication and dosage for their individual needs and follow the recommended administration guidelines for optimal results.
Cost and Availability
When considering Taltz and Cosentyx, cost and availability are important factors to keep in mind.
According to the manufacturer’s website, the list price for a one-month supply of Taltz is $6,600. However, the actual cost may vary depending on insurance coverage and other factors. The makers of Taltz also offer a co-pay assistance program to help with the cost of the medication.
Cosentyx, on the other hand, has a list price of $6,660 per month, with similar caveats regarding insurance coverage and other variables. Like Taltz, the makers of Cosentyx offer a financial assistance program to help with the cost of the medication.
- Both Taltz and Cosentyx are available by prescription only. They are not available over-the-counter.
- Both drugs are covered by Medicare and most private insurance plans. However, coverage may vary depending on the insurance plan. Patients should check with their insurance provider to determine coverage and out-of-pocket costs for each medication.
- The availability of Taltz and Cosentyx may vary by location and pharmacy. Patients may also be required to wait for the medication to be ordered if it is not readily available in stock.
It’s important for patients to communicate with their healthcare provider and insurance company to determine the most cost-effective and accessible treatment option for their specific needs.
| Taltz | Cosentyx | |
|---|---|---|
| List Price (one month supply) | $6,600 | $6,660 |
| Coverage | Most private insurance plans and Medicare | Most private insurance plans and Medicare |
| Availability | Prescription only, availability may vary by location and pharmacy | Prescription only, availability may vary by location and pharmacy |
| Financial Assistance | Co-pay assistance program | Financial assistance program |
Overall, when it comes to cost and availability, both Taltz and Cosentyx have similar factors to consider. It’s important for patients to work closely with their healthcare provider and insurance company to determine the most affordable and accessible treatment option for them.
Efficacy and Patient Satisfaction
If you or a loved one are living with a chronic inflammatory disease such as psoriasis or ankylosing spondylitis, you may be considering treatment with either Taltz or Cosentyx. Both of these drugs are FDA-approved for the treatment of these conditions, but there are some important differences between them that you should be aware of before making a decision.
Efficacy
- Taltz (ixekizumab) is a monoclonal antibody that specifically targets interleukin-17A (IL-17A), a cytokine that plays a key role in the inflammation associated with psoriasis and ankylosing spondylitis. Cosentyx (secukinumab) is also a monoclonal antibody, but it targets a different cytokine called interleukin-17A and interleukin-17F (IL-17A/F).
- In clinical trials, both drugs have been shown to be effective at reducing the symptoms of psoriasis and ankylosing spondylitis. According to a study published in the Journal of the American Academy of Dermatology, after 12 weeks of treatment, 80% of patients with moderate to severe plaque psoriasis who received Taltz saw a significant reduction in their symptoms. Similarly, a study published in the Annals of the Rheumatic Diseases found that 64% of patients with ankylosing spondylitis who received Cosentyx had a significant reduction in their symptoms.
- However, there are some differences in efficacy between the two drugs. For example, a study published in the Journal of the European Academy of Dermatology and Venereology found that Taltz was more effective at reducing symptoms of scalp psoriasis, whereas Cosentyx was more effective at reducing symptoms of nail psoriasis. Additionally, a study published in the British Journal of Dermatology found that Taltz was more effective at achieving complete skin clearance, whereas Cosentyx was more effective at achieving rapid symptom relief.
Patient Satisfaction
When it comes to patient satisfaction, there is some evidence to suggest that Taltz may be preferred by patients over Cosentyx. According to a study published in the Journal of Dermatological Treatment, patients who received Taltz reported a higher level of satisfaction with their treatment than those who received Cosentyx. The study found that Taltz was associated with a higher degree of treatment effectiveness, convenience, and trust in the medication. However, it’s important to note that patient satisfaction can vary widely depending on individual experiences and preferences.
Conclusion
Both Taltz and Cosentyx are effective treatments for psoriasis and ankylosing spondylitis, and the choice between them ultimately depends on individual factors such as symptom severity, response to treatment, and personal preferences. Consulting with a healthcare provider is crucial in determining the best course of treatment for you or your loved one.
| Taltz | Cosentyx | |
|---|---|---|
| Target cytokine | Interleukin-17A | Interleukin-17A/F |
| Effectiveness | More effective at scalp psoriasis and complete skin clearance | More effective at nail psoriasis and rapid symptom relief |
| Patient satisfaction | Associated with higher degree of treatment effectiveness, convenience, and trust in the medication | N/A |
Source: Adapted from Journal of the American Academy of Dermatology, Annals of the Rheumatic Diseases, Journal of the European Academy of Dermatology and Venereology, British Journal of Dermatology, and Journal of Dermatological Treatment.
What is the Difference Between Taltz and Cosentyx?
Q: What are Taltz and Cosentyx?
A: Taltz and Cosentyx are both medications used to treat autoimmune conditions such as psoriasis and psoriatic arthritis.
Q: How do Taltz and Cosentyx work?
A: Taltz and Cosentyx both work by targeting specific proteins in the body that are involved in the immune system response. This helps to reduce inflammation and improve symptoms of autoimmune conditions.
Q: What is the main difference between Taltz and Cosentyx?
A: The main difference between Taltz and Cosentyx is the specific protein they target. Taltz targets a protein called IL-17A, while Cosentyx targets a protein called IL-17A and another called IL-17F.
Q: Are there any other differences between Taltz and Cosentyx?
A: While both medications are injected, the dosing frequency and administration method may differ. Taltz is typically injected once every 4 weeks, while Cosentyx may be injected once every 2-4 weeks. Cosentyx is also available as an autoinjector, while Taltz is currently only available for use with a prefilled syringe or pen.
Q: Are there any side effects to consider with Taltz and Cosentyx?
A: As with any medication, there are potential side effects to consider with both Taltz and Cosentyx. These may include injection site reactions, infections, and allergic reactions. It is important to discuss any potential risks and benefits with your healthcare provider before starting any new medication.
Closing Thoughts
Thanks for reading about the difference between Taltz and Cosentyx. Remember to always consult with your healthcare provider before starting any new medication, and to discuss any questions or concerns you may have. We hope you found this information helpful, and please check back soon for more updates!